GW Pharmaceuticals PLC- (GWPH) Earns Buy Rating from Maxim Group
GW Pharmaceuticals PLC- (NASDAQ:GWPH)‘s stock had its “buy” rating reissued by analysts at Maxim Group in a report released on Thursday. They presently have a $135.00 price objective on the biopharmaceutical company’s stock. Maxim Group’s target price suggests a potential upside of 26.99% from the stock’s previous close.
The analysts wrote, “GW pharmaceuticals announced publication of data from the P3 study of Epidiolex (oral CBD, cannabidiol) in pediatric Dravet Syndrome in The New England Journal of Medicine (NEJM).””
Other research analysts have also recently issued research reports about the company. Zacks Investment Research cut GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research report on Monday, May 15th. Cowen and Company set a $135.00 price target on GW Pharmaceuticals PLC- and gave the company a “buy” rating in a research report on Monday, February 6th. TheStreet cut GW Pharmaceuticals PLC- from a “c-” rating to a “d+” rating in a research report on Wednesday, May 10th. Cantor Fitzgerald set a $208.00 price target on GW Pharmaceuticals PLC- and gave the company a “buy” rating in a research report on Tuesday, February 7th. Finally, Piper Jaffray Companies set a $147.00 price objective on GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research report on Tuesday, February 7th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. GW Pharmaceuticals PLC- presently has a consensus rating of “Buy” and a consensus price target of $144.50.
Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) traded up 1.28% during midday trading on Thursday, reaching $107.67. 226,855 shares of the company traded hands. The stock’s market capitalization is $2.72 billion. GW Pharmaceuticals PLC- has a 1-year low of $79.62 and a 1-year high of $137.88. The stock’s 50-day moving average is $112.43 and its 200-day moving average is $118.77.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.50) by $0.20. GW Pharmaceuticals PLC- had a negative net margin of 702.90% and a negative return on equity of 20.07%. The firm had revenue of $2.04 million during the quarter, compared to analysts’ expectations of $2.07 million. During the same quarter in the prior year, the business earned ($0.06) EPS. The company’s quarterly revenue was down 23.0% compared to the same quarter last year. Equities analysts predict that GW Pharmaceuticals PLC- will post ($5.53) EPS for the current fiscal year.
WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/05/25/gw-pharmaceuticals-plc-gwph-earns-buy-rating-from-maxim-group.html.
A number of hedge funds have recently bought and sold shares of the stock. Capital Research Global Investors boosted its stake in GW Pharmaceuticals PLC- by 14.9% in the third quarter. Capital Research Global Investors now owns 3,017,604 shares of the biopharmaceutical company’s stock valued at $400,527,000 after buying an additional 390,930 shares during the period. Prudential PLC boosted its stake in GW Pharmaceuticals PLC- by 75.8% in the fourth quarter. Prudential PLC now owns 2,050,212 shares of the biopharmaceutical company’s stock valued at $229,111,000 after buying an additional 884,106 shares during the period. Scopia Capital Management LP acquired a new stake in GW Pharmaceuticals PLC- during the third quarter valued at approximately $250,218,000. Deerfield Management Co. boosted its stake in GW Pharmaceuticals PLC- by 47.1% in the second quarter. Deerfield Management Co. now owns 991,800 shares of the biopharmaceutical company’s stock valued at $90,819,000 after buying an additional 317,427 shares during the period. Finally, Janus Capital Management boosted its stake in GW Pharmaceuticals PLC- by 13.3% in the third quarter. Janus Capital Management now owns 833,115 shares of the biopharmaceutical company’s stock valued at $76,121,000 after buying an additional 97,684 shares during the period. Institutional investors own 72.30% of the company’s stock.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.